Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2026-03-01 @ 1:24 AM
Study NCT ID:
NCT02716805
Status:
TERMINATED
Last Update Posted:
2022-10-12
First Post:
2016-03-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-12-13
Start Date Type:
ACTUAL
Primary Completion Date:
2018-02-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-02-16
Completion Date Type:
ACTUAL
First Submit Date:
2016-03-02
First Submit QC Date:
None
Study First Post Date:
2016-03-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-04
Results First Submit QC Date:
None
Results First Post Date:
2019-03-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-03
Last Update Post Date:
2022-10-12
Last Update Post Date Type:
ACTUAL